Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. x. x x. 46/2008 Xx. x. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že dne 1. xxxxx 2017 xxxx xxxxxxxxx ředitelkou XXXXXX oznámeno schválení xxxxxx znění Xxxxxxx X - Seznam xxxxxxxxxx látek x xxxxx xxxxxxx xxx xxx 2018 - Xxxxxxxxxxx standard Mezinárodní xxxxxx proti dopingu xx sportu¹⁾.

S novým xxxxxx Xxxxxxx X xxxxxxxx souhlas Parlament Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx o přijetí xxxx Xxxxxxx X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx x platnost v xxxxxxx s článkem 34 xxxx. 3 Úmluvy xxx 1. ledna 2018. Pro Českou xxxxxxxxx xxxxxxxxx xxxx xxxxx Přílohy I x xxxxxxxx xxx 5. června 2019.

Dnem xxxxxx xxxxxx xxxxx Xxxxxxx I x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx pod č. 80/2017 Sb. m. s.

Anglické xxxxx xxxxxx xxxxx Xxxxxxx X a xxxx xxxxxxx xx xxxxxxx jazyka se xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX ANTIDOPINGOVÝ XXXXX

XXXXXX XXXXXXXXXX XXXXX X METOD XXXXXXX XXX XXX 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx spravován XXXX x bude xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx mezi xxxxxxxxx x francouzskou xxxxx xxxx rozhodující xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx od 1. xxxxx 2018 

XXXXXX ZAKÁZANÝCH XXXXX X METOD XXXXXXX XXX XXX 2018

XXXXXXX ANTIDOPINGOVÝ KODEX

Platný xx 1. ledna 2018

XXXXX X XXXXXX XXXXXXXX STÁLE (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx xx "Specifické xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x M3.

ZAKÁZANÉ XXXXX

X0. NESCHVÁLENÉ LÁTKY

Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx výzkumu xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx xxxxx xxx veterinární použití), xx zakázána xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-diol);

bolasteron;

danazol ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další látky x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (androst-4-en-3,17-dion);

boldenon;

boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx metabolity x xxxxxxx, xxxxxx, ale xx x xxxxxxxx xxxxx na xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM, xxxx. xxxxxxx, XXX-4033, xxxxxxx x XXX140); xxxxxxx; xxxxxxx a xxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

Xxx účely xxxxxxx xxxx sekce: * "exogenní" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ XXXXXXX, XXXXXXXX XXXXX A XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx:

1. Xxxxxxxxxxxxx (XXX) a xxxxxxxxxx ovlivňující erytropoézu, xxxxxx, ale xx x xxxxxxxx pouze xx xx:

1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx na XXX (XXX-Xx, xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)); XXX-xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx (např. XXXX 530 a xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; kobalt; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, např.

K-11706.

1.4 Xxxxxxxxxx TGF - xxxx (TGF - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx vrozeného opravného xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Choriogonadotropin (XX) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin, u xxxx.

2.2 Kortikotropiny x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Růstový xxxxxx (GH), jeho xxxxxxxxx a uvolňující xxxxxxx, xxxxxx, xxx xx s xxxxxxxx xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x hGH 176-191; xxxxxx uvolňující xxxxxxx xxxxxx (XXXX) x jeho xxxxxxx, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (GHS), xxxx. xxxxxxx a xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, ipamorelin a xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx hormonu (GHRP), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxxx faktorů, xxxxxx, xxx xx s xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1) a xxxx analoga

mechanické xxxxxxx xxxxxxx (XXX);

xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (VEGF).

Další xxxxxxx xxxxxxx a xxxxxxxxxx xxxxxxxxx faktorů xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx svalů, xxxxx x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- AGONISTÉ

Všichni xxxxxxxxxx x neselektivní xxxx-2 agonisté, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx zakázáni.

Zahrnují (ale xx s omezením xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; indakaterol; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; vilanterol.

Výjimkou xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx formoterolu x moči x xxxxxxxxxxx xxxxx než 40 xx/xx xxxxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec neprokáže xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxxxxxxx xxxxxx (x inhalaci) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale ne x xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), zahrnující:

Raloxifen;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x omezením xxxxx xx ně.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), xxxx. XXXXX; a Agonisté Xxxxxxxxx delta aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (PPARδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516);

5.2 xxxxxxxx x xxxxxxxx xxxxxxxx;

5.3 xxxxxxxxx;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx diuretika x xxxxxxxxx xxxxx xxxx xxxxxxxx, stejně jako xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, hydroxyethylškrobu a xxxxxxxxx); probenecid, xxx xx s omezením xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; bumetanid; xxxxxxxxx; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx); xxxxxxxxxx x vaptany (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x brinzolamidu)

• Lokálního podání xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx limitem (tj. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx kdykoliv xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx látkou, bude xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto látku xxxxx k té, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI

Zakázané je xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv množství xxxxxxxxx, alogenní (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x jim podobných xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx nebo xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx hemoglobinové xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx ne x omezením xxxxx xx xx. Inhalační xxxxxxxxxxxx kyslíkem zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx s xxxxxxxx komponentami fyzikálními xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Pokus x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx pouze xx xx.

2. Nitrožilní infuze x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx za 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx zvýšení xxxxxxxxxxx výkonu je xxxxxxxx xxxxxxxxxxx:

1. Použití xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx analogů;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, vytvořených x xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x transkripční xxxx xxxxxxxxxxxx regulaci xxxxxx xxxxxxx.

3. Použití xxxxxxxxxx nebo geneticky xxxxxxxxxxxxxx xxxxx;

XXXXX A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 xx S5 a X1 xx M3 xxxxxxxxx xxxx

xxxx Při Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:

ZAKÁZANÉ XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, např. x- a X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx výslovně xxxxxxx x tomto xxxxxxxx, xx Specifickou xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx s xxxxxxxx xxxxx na xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx xxxxxxx (např. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X výjimkou:

• klonidinu

• derivátů xxxxxxxxx x případě xxxxxx xxxxxxxx/xxxxxx použití x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x synefrin: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2018 a nejsou xxxxxxxxxx za Zakázané xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší než 5 mikrogramů x 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx x 1 ml moči.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx při xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

***** Xxxxxxxxxxxxx: xx zakázán, xxxxx jeho koncentrace x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx kanabinoidy, xxxx. delta9-tetrahydrokanabinol (THC) x xxxxxxx xxxxxxxxxxxxxx.

Xxxxx: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx zakázané.

Včetně, xxx xx x xxxxxxxx xxxxx na xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx pouze v xxxxxxxxxxxxx sportech Xxx Xxxxxxx, a xxx xx xx označeno x Xxxx soutěž.

• Automobilový xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx U-rampa x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx xxxxxxxxxx xxxx x xxxxxxxxx xxxx xxx ploutví, xxxxxxxxx xxxxx s xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx xxxx Mimo xxxxxx

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne s xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx předpis x. 36/2019 Xx. m. x. xxxxx účinnosti xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Xx. x. x. byl xxxxxx xxxxxxx xxxxxxxxx č. 32/2023 Sb. m. s. x xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx aktualizováno, xxxxx se xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, xxxxxxx dne 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x anglickém xxxxx a s xxxxxxxxx do českého xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Úmluvy xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.